Diabetes Patients In Europe Were Warned To Be On Alert After Novo Nordisk Announced A Recall Of Several Batches Of Its Novomix Insulin.The Recall Affects Batches Of The Prefilled Insulin Product Novomix30 Flexpen In Austria, Belgium, Czech Republic, Denmark, France, Germany, Iceland, Luxemburg, Netherlands, Norway And Slovakia, While Batches Of Novomix Penfill Have Been Recalled In The Uk And Ireland.Novo Explained That The Recall Was Down To An Incorrect Amount Of Insulin Found In Some (0.14 Per Cent) Of The Products Contained In These Batches.The Financial Impact Of The Recall For Novo Is Unclear, Although The Novomix Managed Revenues Of 2.5Bn Danish Krone (About
